Comparison of Consecutive Therapeutic Effects of Nanoemulsion and Emulsion Cyclosporin in Dry Eye Patients after Short-Term Treatment with Topical Fluorometholone

Table 2

Comparison of therapeutic effects at 4 weeks after treatment with topical FML between nanoemulsion and emulsion CsA groups.

	Group 1 (nanoemulsion CsA)			Group 2 (emulsion CsA)			value
	Baseline	4 weeks after treatment	value	Baseline	4 weeks after treatment	value
BCVA (logMAR)	0.08 ± 0.11	0.06 ± 0.07	0.348	0.12 ± 0.11	0.10 ± 0.10	0.407	0.132
IOP (mmHg)	9.4 ± 1.6	9.6 ± 1.4	0.873	9.8 ± 2.4	9.6 ± 2.1	0.723	0.731
SANDE (pts)	73.9 ± 17.8	51.2 ± 21.3	0.002	67.8 ± 24.1	49.4 ± 15.8	<0.001	0.588
TBUT (sec)	2.6 ± 1.1	4.3 ± 1.5	0.001	3.1 ± 1.4	4.8 ± 1.5	<0.001	0.296
Schirmer (mm)	9.0 ± 7.6	11.6 ± 10.0	0.396	8.9 ± 7.2	6.1 ± 4.9	0.008	0.037
CSS (pts)	0.6 ± 1.1	0.4 ± 0.8	0.408	0.3 ± 0.7	0.4 ± 0.9	0.750	0.999
MGD grade	1.8 ± 0.4	1.1 ± 0.6	0.001	1.9 ± 0.4	1.0 ± 0.3	<0.001	0.536
MG expression (pts)	2.6 ± 1.1	1.4 ± 0.7	0.001	2.3 ± 0.7	1.4 ± 0.5	<0.001	0.752

Values are presented as mean ± standard deviation. Intragroup analysis (Wilcoxon signed-rank test); intergroup analysis (Mann–Whitney test). FML: 0.1% fluorometholone; BCVA: best corrected visual acuity; IOP: intraocular pressure; SANDE: symptom assessment in dry eye; TBUT: tear film breakup time; CSS: corneal staining score (NEI scale, 0–15) MGD: meibomian gland dysfunction; MG: meibomian gland. Statistically significant.